Circulating Tumor DNA Screening for Targeted Therapy A Promising Approach in Cancer Patients Care
Article Sidebar
Main Article Content
Abstract
Circulating tumor DNA screening involves the analysis of tumor-derived DNA fragments that circulate in the bloodstream. By meticulously sequencing and scrutinizing this DNA, cancer specialists can uncover mutations and this technique have propelled it as a promising avenue for detecting genetic anomalies in cancer patients, while also serving as an approach to targeted therapy. Furthermore, there is potential for detecting residual diseases at a very minimal level, monitoring recurrence, and tracking the progression of cancer from its early stages. It assists medical practitioners in tailoring treatment strategies on time, provides reliable test outcomes for pre- and post-treatment, and facilitates more rapid assessment of treatment efficacy. Nevertheless, this screening test still faces limitations concerning sensitivity and testing standards, necessitating further development.
This article aimed to equip nurses with comprehensive insights into the realm of bloodstream tumor DNA screening, enable them to fulfill a role as educator and caregiver for accurate understanding of the patients, as well as promote and support patient participation in informed treatment planning decisions.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
เนื้อหาและข้อมูลในบทความที่ลงตีพิมพ์ในวารสารการพยาบาลและสุขภาพ สสอท. ถือเป็นข้อคิดเห็นและความรับผิดชอบของผู้เขียนบทความโดยตรง ซึ่งกองบรรณาธิการวารสารไม่จำเป็นต้องเห็นด้วย หรือร่วมรับผิดชอบใดๆ
บทความ ข้อมูล เนื้อหา รูปภาพ ฯลฯ ที่ได้รับการตีพิมพ์ในวารสารการพยาบาลและสุขภาพ สสอท. ถือเป็นลิขสิทธิ์ของวารสารการพยาบาลและสุขภาพ สสอท. หากบุคคลหรือหน่วยงานใดต้องการนำทั้งหมด หรือส่วนหนึ่งส่วนใดไปเผยแพร่ หรือเพื่อกระทำการใดๆ จะต้องได้รับอนุญาตเป็นลายลักษณ์อักษรจากวารสารการพยาบาลและสุขภาพ สสอท. ก่อนเท่านั้น
References
Beer, T. M. (2020). Novel blood-based early cancer detection: diagnostics in development. The American Journal of Managed Care, 26(14 Suppl), S292-S299. doi:10.37765/ajmc.2020.88533
Campos-Carrillo, A., Weitzel, J. N., Sahoo, P., Rockne, R., Mokhnatkin, J. V., Murtaza, M., … Slavin, T. P. (2020). Circulating tumor DNA as an early cancer detection tool. Pharmacology Therapeutics, 207, 107458. doi:10.1016/j.pharmthera.2019.107458
Chen, M., & Zhao, H. (2019). Next-generation sequencing in liquid biopsy: Cancer screening and early detection. Human genomics, 13, 34.
Constantin, N., Sina, A. A. I., Korbie, D., & Trau, M. (2022). Opportunities for early cancer detection: The rise of ctDNA methylation-based pan-cancer screening technologies. Epigenomes, 6(1), 6.
Cohen, J. D., Li, L., Wang, Y., Thoburn, C., Afsari, B., Danilova, L., ... Papadopoulos, N. (2018). Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science, 359(6378), 926-930.
Cui, W., Milner-Watts, C., McVeigh, T. P., Minchom, A., Bholse, J., Davidson, M., … O'Brien, M. (2022). A pilot of Blood-First diagnostic cell free DNA (ctDNA) next generation sequencing (NGS) in patients with suspected advanced lung cancer. Lung Cancer, 165, 34-42. doi:10.1016/j.lungcan.2022.01.009
Eraslan, G., Avsec, Ž., Gagneur, J., & Theis, F. J. (2019). Deep learning: New computational modelling techniques for genomics. Nature Reviews Genetics, 20(7), 389-403.
Michela, B. (2021). Liquid biopsy: a family of possible diagnostic tools. Diagnostics, 11(8), 1391.
Nguyen, T. H. H., Lu, Y. T., Le, V. H., Bui, V. Q., Nguyen, L. H., Pham, N. H., … Tran, L. S. (2023). Clinical validation of a ctDNA-Based Assay for Multi-Cancer Detection: An interim report from a Vietnamese longitudinal prospective cohort study of 2795 participants. Cancer Investigation, 41(3), 232-248. doi:10.1080/07357907.2023.2173773
Routhier, E., & Mozziconacci, J. (2022). Genomics enters the deep learning era. PeerJ, 10, e13613.
Soerensen, A. V., Donskov, F., Hermann, G. G., Jensen, N. V., Petersen, A., Spliid, H., … Geertsen, P. F. (2014). Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: Results from the Danish Renal Cancer Group (DARENCA) study-2. European Journal of Cancer, 50(3), 553-562. doi:10.1016/j.ejca.2013.10.010
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 71(3), 209-249.
Widschwendter, M., Zikan, M., Wahl, B., Lempiäinen, H., Paprotka, T., Evans, I., ... & Wittenberger, T. (2017). The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer. Genome Medicine, 9, 1-14